Josep Darba

Summary

Affiliation: Universitat de Barcelona
Country: Spain

Publications

  1. doi request reprint Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective
    Josep Darba
    Department of Economics, Universidad de Barcelona, Barcelona, Spain
    Adv Ther 31:1-29. 2014
  2. doi request reprint Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials
    Josep Darba
    Departamento de Economia, Universidad de Barcelona, Espana
    Rev Psiquiatr Salud Ment 4:126-43. 2011
  3. ncbi request reprint A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs
    Josep Darba
    Department of Economics, University of Barcelona, Spain
    Ann Clin Psychiatry 25:17-26. 2013
  4. doi request reprint Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain
    Josep Darba
    Universitat de Barcelona, Barcelona, Spain
    J Clin Pharmacol 52:566-75. 2012
  5. ncbi request reprint [Use of probabilistic methods in economic evaluation of health technologies]
    Josep Darba
    Departamento de Teoría Económica, Universitat de Barcelona, Barcelona, Espana
    Gac Sanit 20:74-7. 2006
  6. doi request reprint Patient preferences for osteoporosis in Spain: a discrete choice experiment
    J Darba
    Department of Economics, Universitat de Barcelona, Diagonal 690, 08034 Barcelona, Spain
    Osteoporos Int 22:1947-54. 2011
  7. doi request reprint Epidemiology and societal costs of gastroesophageal reflux disease and Barrett's syndrome in Germany, Italy and Spain
    Josep Darba
    Universitat de Barcelona, Diagonal 690, 08034, Barcelona, Spain
    Expert Rev Pharmacoecon Outcomes Res 11:225-32. 2011

Detail Information

Publications9

  1. doi request reprint Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective
    Josep Darba
    Department of Economics, Universidad de Barcelona, Barcelona, Spain
    Adv Ther 31:1-29. 2014
    ..The aim of this study was to conduct a systematic review to evaluate the cost-effectiveness of pregabalin associated with the treatment of its labeled indications from a societal perspective in Spain...
  2. doi request reprint Efficacy of second-generation-antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials
    Josep Darba
    Departamento de Economia, Universidad de Barcelona, Espana
    Rev Psiquiatr Salud Ment 4:126-43. 2011
    ..To determine whether second-generation-antipsychotics (SGAs) are effective for negative symptoms treatment in schizophrenia...
  3. ncbi request reprint A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs
    Josep Darba
    Department of Economics, University of Barcelona, Spain
    Ann Clin Psychiatry 25:17-26. 2013
    ..The risk for cardiovascular (CV) events has been shown to be considerably higher among schizophrenia patients than the general population...
  4. doi request reprint Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain
    Josep Darba
    Universitat de Barcelona, Barcelona, Spain
    J Clin Pharmacol 52:566-75. 2012
    ..Direct medical costs for IVIGs were approximately 91.8 million €. Drug costs represented 94% of total costs. The choice for a certain IVIG treatment depends on individual patient characteristics and cost considerations...
  5. ncbi request reprint [Use of probabilistic methods in economic evaluation of health technologies]
    Josep Darba
    Departamento de Teoría Económica, Universitat de Barcelona, Barcelona, Espana
    Gac Sanit 20:74-7. 2006
    ..This kind of information is represented in the cost-effectiveness acceptability curve, which indicates the probability of a health technology being cost-effective for a particular quality-adjusted life year value...
  6. doi request reprint Patient preferences for osteoporosis in Spain: a discrete choice experiment
    J Darba
    Department of Economics, Universitat de Barcelona, Diagonal 690, 08034 Barcelona, Spain
    Osteoporos Int 22:1947-54. 2011
    ..All attributes included as type and place of drug administration as well as costs showed to be significant predictors of choice. Spanish osteoporosis patients have well-defined preferences and accept trade-offs among attributes...
  7. doi request reprint Epidemiology and societal costs of gastroesophageal reflux disease and Barrett's syndrome in Germany, Italy and Spain
    Josep Darba
    Universitat de Barcelona, Diagonal 690, 08034, Barcelona, Spain
    Expert Rev Pharmacoecon Outcomes Res 11:225-32. 2011
    ..To estimate the economic consequences for society arising from populations with poorly treated gastroesophageal reflux disease (GERD) and Barrett's esophagus in Germany, Italy and Spain...